Commonly used titration schemes may not be optimized for the ultra-rapid time-action profile of URLi

This phase 2 study assessed time in range using continuous glucose monitoring with postprandial-focused titration of URLi in combination with degludec in people with type 1 diabetes

URLi demonstrated improved overall glycemic control without evidence of increased hypoglycemia/time below range, as well as reduced overall postprandial glucose excursions

Treatment with URLi in a basal-bolus regimen using a dosing algorithm focused on postprandial glucose targets was efficacious and well tolerated in people with type 1 diabetes